Advicenne S.A. (3MM.F)

1.6620 +0.0100 (+0.61%) As of 09:59AM CEST. Market open.

Advicenne S.A.

3ème étage 262
Rue du Faubourg Saint-Honore
Paris 75008
France
33 1 85 73 36 20
https://www.advicenne.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 21

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Didier Laurens	CEO, MD, General Director & Director	181.84k	N/A	1967
Mr. Laurent Cassedanne	Deputy CEO, Deputy GM & Head Pharmacist	152.74k	N/A	N/A
Isabelle Kervella	Chief Financial Officer	N/A	N/A	N/A
Dr. André Ulmann M.D., Ph.D.	Chief Medical Officer & Non-Voting Director	N/A	N/A	1950
Ms. Hege Hellstrom	Chief Commercial Officer	N/A	N/A	1965

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. Its main drug candidate is Sibnayal, which has completed phase III clinical trial for the treatment of distal renal tubular acidosis, as well as cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.

Corporate Governance

Advicenne S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.